No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
VIR Vir Biotechnology
- 8.230
- +0.600+7.86%
Close Apr 26 16:00 ET
- 8.220
- -0.010-0.12%
Post 18:34 ET
1.12BMarket Cap-1793P/E (TTM)
8.275High7.640Low1.11MVolume7.740Open7.630Pre Close9.02MTurnover1.23%Turnover RatioLossP/E (Static)135.84MShares27.48052wk High0.70P/B738.92MFloat Cap7.61052wk Low--Dividend TTM89.78MShs Float141.010Historical High--Div YieldTTM8.32%Amplitude7.610Historical Low8.157Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
What Makes Vir Biotechnology (VIR) a New Buy Stock
Vir Biotechnology Announces CFO Departure and Board Expansion
Express News | Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.d. and Ramy Farid, Ph.d. to Its Board of Directors
Express News | Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution
In the last year, many Vir Biotechnology, Inc. (NASDAQ:VIR) insiders sold a substantial stake in the company which may have sparked shareholders' attention. When analyzing insider transactions, it i
Vir Biotechnology Inc CEO Backer De Sells 72,995 Shares
Comments
I think CFO is actually fired.
$Vir Biotechnology(VIR.US$ They need better cost control and accounting practice to boost share price to a reasonable level (say 20). Section is bad because of Biden, but literally science is priced at 0 for VIR. Active investor should interfere. I’ll vote all Against in proxy, as I am not happy at all.
good earnings but i don’t like
$Vir Biotechnology(VIR.US$ small scale experiments are good.
no idea why they issue cost guidance (huge) without revenue guidance. Stupid.
I don’t like new management goes back to clinical stage biotech. They hire too many people and relocate position to high salary area. AI expert in San Francisco, come on… If not sotrovimab and help of GSK made huge money, this company would have doomed.(if not stopped by Biden, would have been 40 dollar per share). I’ll start...
no idea why they issue cost guidance (huge) without revenue guidance. Stupid.
I don’t like new management goes back to clinical stage biotech. They hire too many people and relocate position to high salary area. AI expert in San Francisco, come on… If not sotrovimab and help of GSK made huge money, this company would have doomed.(if not stopped by Biden, would have been 40 dollar per share). I’ll start...
ColumnsToday's Morning Movers and Top Ratings: MSFT, ZI, AAL, HSY and More
Morning Movers
Gapping up
$ZoomInfo(ZI.US$ The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. “We believe it is a classic self-help story that is set to outperform,” the analyst wrote, underscoring the company’s revenue growth reacceleration and new AI products as potential catalysts.
$Boeing(BA.US$ stock rose 0.9% after Ryanair, Europe's largest airline by passenger number...
Gapping up
$ZoomInfo(ZI.US$ The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. “We believe it is a classic self-help story that is set to outperform,” the analyst wrote, underscoring the company’s revenue growth reacceleration and new AI products as potential catalysts.
$Boeing(BA.US$ stock rose 0.9% after Ryanair, Europe's largest airline by passenger number...
20
Upcoming Ph 2 readouts in Q1 2024…
$Cellectar BioSciences(CLRB.US$ Phase 2
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
$Regenxbio(RGNX.US$ Phase 2
$Leap Therapeutics(LPTX.US$ Phase 2
$4D Molecular Therapeutics(FDMT.US$ Phase 2
$Adverum Biotechnologies(ADVM.US$ Phase 2
$Denali Therapeutics(DNLI.US$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US$ Phase 2
$Xencor(XNCR.US$ Phase 2
$Harmony Biosciences(HRMY.US$ Phase 2
$Alnylam Pharmaceuticals(ALNY.US$ Phase 2
$Disc Medicine(IRON.US$ Phase 2
$Atea Pharmaceuticals(AVIR.US$ Phase 2
$Allakos(ALLK.US$ Phase 2...
36
6
The multiple insider sales in Vir Biotechnology and zero buying activity in the last year may be a concern for potential investors. However, a fair level of insider ownership suggests a reasonable alignment of interests with shareholders.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg